A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

Investigational New Drugs

Volumn 15, Issue 4, 1997, Pages 353-355

  Berg, William J ^a   Schwartz, Lawrence H ^b   Amsterdam, Alison ^a   Mazumdar, Madhu ^b   Vlamis, Vaia ^b   Law, Teresa Murray ^a   Nanus, David M ^a,c,d   Motzer, Robert J ^a,c,d  

^a Division of Solid Tumor Oncology

^b Department of Radiology ^*

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Advanced renal cell carcinoma; Retinoic acid

Indexed keywords

ANTINEOPLASTIC AGENT; ISOTRETINOIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DRY SKIN; FEMALE; HUMAN; HYPERLIPIDEMIA; KIDNEY CARCINOMA; LIFE EXPECTANCY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRETINOIN;

EID: 0031414828     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005902022076     Document Type: Article

References (9)

1. Motzer RJ, Bander NH, Nanus DM: Medical progress: Renal-cell carcinoma. New Engl J Med 335:865-875, 1996
2. Motzer RJ, Vogelzang NJ: Chemotherapy for renal cell carcinoma. In: Raghaven D, Scher HI, Leibel SA, Lange P (eds) Principles and Practice of Genitourinary Oncology. Lippincott-Raven, Philadelphia, 1997, pp 885-896
3. Motzer RJ, Schwartz L, Murray Law T, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM: Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950-1957, 1995
4. Murray Law T, Motzer RJ, Minasian LM, Mazumdar M, Lyn P, Kampel L: Risk stratification in advanced renal cell carcinoma: A single institution study of 237 patients (Abstract). Proc Amer Soc Clin Oncol 13:243, 1994
5. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE: Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368-1375, 1993
6. Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ: A phase II trial of interleukin-2 and interferon alfa 2a in patients wit advanced renal cell carcinoma. J Clin Oncol 10:1124-1130, 1992
7. Murray Law T, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang N, Bajorin DF: Phase III randomized trial of interleukin-2 with or without lymphine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76:824-832, 1995
8. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207-214, 1981
9. Hoffman AD, Engelstein D, Bogenrieder T, Papandreou CN, Steckelman E, Dave A, Motzer RJ, Dmitrovsky E, Albino A, Nanus DM: Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 2:1077-1082, 1996